1765 related articles for article (PubMed ID: 21078787)
41. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
44. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery.
Kim DH; Son SH; Kim CY; Hong CM; Oh JR; Song BI; Kim HW; Jeong SY; Lee SW; Lee J; Ahn BC
Ann Surg Oncol; 2014 Feb; 21(2):589-96. PubMed ID: 24046125
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.
Cornelis F; Sotirchos V; Violari E; Sofocleous CT; Schoder H; Durack JC; Siegelbaum RH; Maybody M; Humm J; Solomon SB
J Nucl Med; 2016 Jul; 57(7):1052-7. PubMed ID: 26912433
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer.
Pou Ucha JL; Nogueiras Alonso JM; Alvarez Paez AM; Suarez Arfenoni BA; Puig AS; Lopez Lopez AM; Barandela Salgado J; Campos Villarino LM; Casal Rivas M; Guitian Iglesias R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):301-7. PubMed ID: 23084012
[TBL] [Abstract][Full Text] [Related]
47. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.
Deandreis D; Leboulleux S; Dromain C; Auperin A; Coulot J; Lumbroso J; Deschamps F; Rao P; Schlumberger M; de Baère T
Radiology; 2011 Jan; 258(1):270-6. PubMed ID: 21045185
[TBL] [Abstract][Full Text] [Related]
48. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?
Yoo DC; Dupuy DE; Hillman SL; Fernando HC; Rilling WS; Shepard JA; Siegel BA
AJR Am J Roentgenol; 2011 Aug; 197(2):334-40. PubMed ID: 21785078
[TBL] [Abstract][Full Text] [Related]
49. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
50. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
[TBL] [Abstract][Full Text] [Related]
51. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
Schoellnast H; Larson SM; Nehmeh SA; Carrasquillo JA; Thornton RH; Solomon SB
Cardiovasc Intervent Radiol; 2011 Feb; 34 Suppl 2():S182-5. PubMed ID: 20508937
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
53. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
54. PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation.
Nielsen K; van Tilborg AA; Scheffer HJ; Meijerink MR; de Lange-de Klerk ES; Meijer S; Comans EF; van den Tol MP
Eur J Radiol; 2013 Dec; 82(12):2169-75. PubMed ID: 24021269
[TBL] [Abstract][Full Text] [Related]
55. Predicting pleural invasion using HRCT and 18F-FDG PET/CT in lung adenocarcinoma with pleural contact.
Tanaka T; Shinya T; Sato S; Mitsuhashi T; Ichimura K; Soh J; Toyooka S; Kaji M; Miyoshi S; Kanazawa S
Ann Nucl Med; 2015 Nov; 29(9):757-65. PubMed ID: 26142739
[TBL] [Abstract][Full Text] [Related]
56. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
[TBL] [Abstract][Full Text] [Related]
57. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
59. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
60. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
